Published in N Engl J Med on February 24, 2003
Epidemiology of Venous Thromboembolism | NCT00041457
Prevention of Recurrent Venous Thromboembolism (PREVENT) | NCT00000614
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg (2005) 2.04
Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med (2003) 2.00
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med (2007) 1.70
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol (2007) 1.50
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol (2005) 1.29
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
CLIA-tested genetic variants on commercial SNP arrays: potential for incidental findings in genome-wide association studies. Genet Med (2010) 1.21
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood (2011) 1.14
Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J (2013) 1.05
Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract (2004) 1.03
EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study. J Gen Intern Med (2008) 1.03
Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost (2010) 1.02
Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol (2010) 0.98
Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med (2014) 0.98
Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop (2012) 0.91
Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res (2011) 0.88
Predicting the risk of venous thromboembolism recurrence. Am J Hematol (2012) 0.88
Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore) (2014) 0.86
Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med (2008) 0.86
Optimal duration of anticoagulation after venous thromboembolism. Circulation (2011) 0.85
Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study. BMC Nephrol (2012) 0.83
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol. BMC Pregnancy Childbirth (2012) 0.82
Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study. Thromb J (2005) 0.81
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. PLoS One (2014) 0.80
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol (2012) 0.79
Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulm Circ (2013) 0.78
The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range? J Arthroplasty (2014) 0.77
Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol (2008) 0.77
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. Eur J Clin Pharmacol (2006) 0.77
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
Barriers to the use of warfarin: potential solutions. J Interv Card Electrophysiol (2004) 0.76
Acute deep vein thrombosis cases in the real world. Semin Intervent Radiol (2012) 0.76
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76
Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009). Thromb Res (2015) 0.75
Low-dose warfarin prevents recurrent thromboembolism. J Fam Pract (2003) 0.75
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep (2016) 0.75
Life-threatening aortic thrombosis in a trauma patient homozygous for factor V Leiden mutation: Case report. Thromb J (2011) 0.75
Long-term, low-intensity warfarin after idiopathic venous thromboembolism. CMAJ (2003) 0.75
Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. J Thromb Haemost (2014) 0.75
Optimal duration of anticoagulation in patients with venous thromboembolism. Indian J Med Res (2011) 0.75
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Bleeding and clotting in hereditary hemorrhagic telangiectasia. World J Clin Cases (2015) 0.75
Stopping anticoagulant therapy after an unprovoked venous thromboembolism. CMAJ (2008) 0.75
New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol (2016) 0.75
Warfarin for venous thromboembolism - walking the dosing tightrope. N Engl J Med (2003) 0.75
Low-intensity warfarin therapy prevented recurrent venous thromboembolism. ACP J Club (2003) 0.75
Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases. Curr Control Trials Cardiovasc Med (2004) 0.75
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study). BMC Cardiovasc Disord (2013) 0.75
Thrombosis - Besieged but Poorly Understood. Front Cardiovasc Med (2014) 0.75
Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach. Clin Chim Acta (2009) 0.75
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. Thrombosis (2010) 0.75
Long-term management of venous thromboembolism. Rev Cardiovasc Med (2004) 0.75
The treatment of deep vein thrombosis in the pelvis and leg. Dtsch Arztebl Int (2008) 0.75
Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. J Gen Intern Med (2003) 0.75
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Duration of anticoagulation for venous thromboembolic events. Circulation (2014) 0.75
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes. Intern Emerg Med (2017) 0.75
Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol (2017) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology (2005) 13.05
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med (2002) 8.37
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2011) 7.30
Withdrawal of nonfutile life support after attempted suicide. Am J Bioeth (2013) 7.26
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA (2005) 5.46
Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence. J Am Coll Cardiol (2011) 5.30
Genomewide association studies of stroke. N Engl J Med (2009) 5.29
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med (2005) 4.80
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation (2010) 4.66
Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med (2008) 4.64
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol (2011) 4.61
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med (2002) 3.96
Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2007) 3.90
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med (2006) 3.70
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke (2006) 3.67
International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica (2009) 3.63
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet (2008) 3.33
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA (2006) 3.26
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med (2002) 3.15
A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med (2005) 3.14
Impending paradoxical embolism: systematic review of prognostic factors and treatment. Chest (2009) 3.09
Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med (2013) 3.08
Association of race and sex with risk of incident acute coronary heart disease events. JAMA (2012) 3.07
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med (2002) 3.04
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 2.98
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
Pulmonary embolism and deep vein thrombosis. Lancet (2012) 2.97
Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation (2007) 2.93
Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87